ID

16773

Description

Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00199797

Link

https://clinicaltrials.gov/show/NCT00199797

Keywords

Versions (1)
  1. 8/5/16 8/5/16 -
Uploaded on

August 5, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Colorectal Cancer NCT00199797

English

Eligibility Colorectal Cancer NCT00199797

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients will be eligible for enrollment if they fulfill all of the following criteria:
Description

criteria Fulfill

Data type

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
1. metastatic colorectal cancer
Description

Colorectal cancer metastatic

Data type

boolean

Alias
UMLS CUI [1]
C0948380
2. histologically or cytologically proven colorectal cancer
Description

Colorectal Carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0009402
3. expected survival of at least 4 months.
Description

Survival time Expected

Data type

boolean

Alias
UMLS CUI [1,1]
C2919552
UMLS CUI [1,2]
C1517001
4. not more than 2 different pretreatment regimens
Description

Pretreatment Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C3539076
UMLS CUI [1,2]
C1265611
5. ecog performance status 0-2.
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
6. within the 2 weeks prior to the first dose of hua33, the following vital laboratory parameters:
Description

A33 monoclonal antibody

Data type

boolean

Alias
UMLS CUI [1]
C0392959
lab parameter range
Description

Laboratory Results

Data type

boolean

Alias
UMLS CUI [1]
C1254595
neutrophil count > 1.5 x 109/l
Description

Absolute neutrophil count

Data type

boolean

Alias
UMLS CUI [1]
C0948762
platelet count > 150 x 109/l
Description

Platelet Count measurement

Data type

boolean

Alias
UMLS CUI [1]
C0032181
serum bilirubin < 2 mg/dl
Description

Serum total bilirubin measurement

Data type

boolean

Alias
UMLS CUI [1]
C1278039
creatinine clearance >50 ml/ min
Description

Creatinine clearance measurement

Data type

boolean

Alias
UMLS CUI [1]
C0373595
7. age ≥ 18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
8. able and willing to give valid written informed consent
Description

Informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients will be excluded from the study for any of the following reasons:
Description

Exclusion Reasons

Data type

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C0392360
1. untreated active metastatic disease to the central nervous system defined as new or enlarging lesions on ct or mri.
Description

CNS metastases | New Lesion X-Ray Computed Tomography | Lesion Enlarged X-Ray Computed Tomography | New Lesion Magnetic Resonance Imaging | Lesion Enlarged Magnetic Resonance Imaging

Data type

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2,1]
C2986548
UMLS CUI [2,2]
C0040405
UMLS CUI [3,1]
C0221198
UMLS CUI [3,2]
C0442800
UMLS CUI [3,3]
C0040405
UMLS CUI [4,1]
C2986548
UMLS CUI [4,2]
C0024485
UMLS CUI [5,1]
C0221198
UMLS CUI [5,2]
C0442800
UMLS CUI [5,3]
C0024485
2. surgery or radiotherapy of brain metastases within 3 months prior to the first dose of hua33.
Description

Operative Surgical Procedures Metastatic malignant neoplasm to brain | Therapeutic radiology procedure Metastatic malignant neoplasm to brain | A33 monoclonal antibody

Data type

boolean

Alias
UMLS CUI [1,1]
C0543467
UMLS CUI [1,2]
C0220650
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C0220650
UMLS CUI [3]
C0392959
3. metastatic disease involving > 50% of liver volume.
Description

Neoplasm Metastasis Involvement with Liver

Data type

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C1314939
UMLS CUI [1,3]
C0023884
4. other serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders.
Description

Illness Serious | Communicable Diseases Serious Requirement Antibiotics | Blood Coagulation Disorders

Data type

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0205404
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C0205404
UMLS CUI [2,3]
C1514873
UMLS CUI [2,4]
C0003232
UMLS CUI [3]
C0005779
5. chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing (6 weeks for nitrosoureas).
Description

Chemotherapy | Therapeutic radiology procedure | Immunotherapy | Nitrosoureas

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1522449
UMLS CUI [3]
C0021083
UMLS CUI [4]
C0028210
6. previous treatment with oxaliplatin.
Description

oxaliplatin

Data type

boolean

Alias
UMLS CUI [1]
C0069717
7. previous treatment with hua33 monoclonal antibody or antibody fragment.
Description

A33 monoclonal antibody | A33 monoclonal antibody Fragment

Data type

boolean

Alias
UMLS CUI [1]
C0392959
UMLS CUI [2,1]
C0392959
UMLS CUI [2,2]
C0332255
8. concomitant treatment with systemic corticosteroids. topical or inhalational corticosteroids are permitted.
Description

systemic steroids | Topical corticosteroids | inhaled steroids

Data type

boolean

Alias
UMLS CUI [1]
C2825233
UMLS CUI [2]
C0304604
UMLS CUI [3]
C2065041
9. known hiv, hepatitis b or c positivity.
Description

HIV Seropositivity | Hepatitis B positive | Hepatitis C positive

Data type

boolean

Alias
UMLS CUI [1]
C0019699
UMLS CUI [2]
C0856706
UMLS CUI [3]
C1112419
10. mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
Description

Mental impairment Informed Consent Limited | Mental impairment Protocol Compliance Limited

Data type

boolean

Alias
UMLS CUI [1,1]
C1112722
UMLS CUI [1,2]
C0021430
UMLS CUI [1,3]
C0439801
UMLS CUI [2,1]
C1112722
UMLS CUI [2,2]
C0525058
UMLS CUI [2,3]
C0439801
11. lack of availability of the patient for clinical and laboratory follow-up assessment.
Description

Follow-up Patient Availability Lack

Data type

boolean

Alias
UMLS CUI [1,1]
C3274571
UMLS CUI [1,2]
C0030705
UMLS CUI [1,3]
C0470187
UMLS CUI [1,4]
C0332268
12. participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing.
Description

Study Subject Participation Status | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
13. pregnancy or breastfeeding.
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
14. women of childbearing potential: refusal or inability to use effective means of contraception.
Description

Childbearing Potential Contraceptive methods Refused | Childbearing Potential Contraceptive methods Unable

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C1705116
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0700589
UMLS CUI [2,3]
C1299582
Back to the top of the page

Similar models

Eligibility Colorectal Cancer NCT00199797

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
criteria Fulfill
Item
patients will be eligible for enrollment if they fulfill all of the following criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Colorectal cancer metastatic
Item
1. metastatic colorectal cancer
boolean
C0948380 (UMLS CUI [1])
Colorectal Carcinoma
Item
2. histologically or cytologically proven colorectal cancer
boolean
C0009402 (UMLS CUI [1])
Survival time Expected
Item
3. expected survival of at least 4 months.
boolean
C2919552 (UMLS CUI [1,1])
C1517001 (UMLS CUI [1,2])
Pretreatment Quantity
Item
4. not more than 2 different pretreatment regimens
boolean
C3539076 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
ECOG performance status
Item
5. ecog performance status 0-2.
boolean
C1520224 (UMLS CUI [1])
A33 monoclonal antibody
Item
6. within the 2 weeks prior to the first dose of hua33, the following vital laboratory parameters:
boolean
C0392959 (UMLS CUI [1])
Laboratory Results
Item
lab parameter range
boolean
C1254595 (UMLS CUI [1])
Absolute neutrophil count
Item
neutrophil count > 1.5 x 109/l
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelet count > 150 x 109/l
boolean
C0032181 (UMLS CUI [1])
Serum total bilirubin measurement
Item
serum bilirubin < 2 mg/dl
boolean
C1278039 (UMLS CUI [1])
Creatinine clearance measurement
Item
creatinine clearance >50 ml/ min
boolean
C0373595 (UMLS CUI [1])
Age
Item
7. age ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Informed consent
Item
8. able and willing to give valid written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Exclusion Reasons
Item
patients will be excluded from the study for any of the following reasons:
boolean
C2828389 (UMLS CUI [1,1])
C0392360 (UMLS CUI [1,2])
CNS metastases | New Lesion X-Ray Computed Tomography | Lesion Enlarged X-Ray Computed Tomography | New Lesion Magnetic Resonance Imaging | Lesion Enlarged Magnetic Resonance Imaging
Item
1. untreated active metastatic disease to the central nervous system defined as new or enlarging lesions on ct or mri.
boolean
C0686377 (UMLS CUI [1])
C2986548 (UMLS CUI [2,1])
C0040405 (UMLS CUI [2,2])
C0221198 (UMLS CUI [3,1])
C0442800 (UMLS CUI [3,2])
C0040405 (UMLS CUI [3,3])
C2986548 (UMLS CUI [4,1])
C0024485 (UMLS CUI [4,2])
C0221198 (UMLS CUI [5,1])
C0442800 (UMLS CUI [5,2])
C0024485 (UMLS CUI [5,3])
Operative Surgical Procedures Metastatic malignant neoplasm to brain | Therapeutic radiology procedure Metastatic malignant neoplasm to brain | A33 monoclonal antibody
Item
2. surgery or radiotherapy of brain metastases within 3 months prior to the first dose of hua33.
boolean
C0543467 (UMLS CUI [1,1])
C0220650 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0220650 (UMLS CUI [2,2])
C0392959 (UMLS CUI [3])
Neoplasm Metastasis Involvement with Liver
Item
3. metastatic disease involving > 50% of liver volume.
boolean
C0027627 (UMLS CUI [1,1])
C1314939 (UMLS CUI [1,2])
C0023884 (UMLS CUI [1,3])
Illness Serious | Communicable Diseases Serious Requirement Antibiotics | Blood Coagulation Disorders
Item
4. other serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders.
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C1514873 (UMLS CUI [2,3])
C0003232 (UMLS CUI [2,4])
C0005779 (UMLS CUI [3])
Chemotherapy | Therapeutic radiology procedure | Immunotherapy | Nitrosoureas
Item
5. chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing (6 weeks for nitrosoureas).
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C0028210 (UMLS CUI [4])
oxaliplatin
Item
6. previous treatment with oxaliplatin.
boolean
C0069717 (UMLS CUI [1])
A33 monoclonal antibody | A33 monoclonal antibody Fragment
Item
7. previous treatment with hua33 monoclonal antibody or antibody fragment.
boolean
C0392959 (UMLS CUI [1])
C0392959 (UMLS CUI [2,1])
C0332255 (UMLS CUI [2,2])
systemic steroids | Topical corticosteroids | inhaled steroids
Item
8. concomitant treatment with systemic corticosteroids. topical or inhalational corticosteroids are permitted.
boolean
C2825233 (UMLS CUI [1])
C0304604 (UMLS CUI [2])
C2065041 (UMLS CUI [3])
HIV Seropositivity | Hepatitis B positive | Hepatitis C positive
Item
9. known hiv, hepatitis b or c positivity.
boolean
C0019699 (UMLS CUI [1])
C0856706 (UMLS CUI [2])
C1112419 (UMLS CUI [3])
Mental impairment Informed Consent Limited | Mental impairment Protocol Compliance Limited
Item
10. mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
boolean
C1112722 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,3])
C1112722 (UMLS CUI [2,1])
C0525058 (UMLS CUI [2,2])
C0439801 (UMLS CUI [2,3])
Follow-up Patient Availability Lack
Item
11. lack of availability of the patient for clinical and laboratory follow-up assessment.
boolean
C3274571 (UMLS CUI [1,1])
C0030705 (UMLS CUI [1,2])
C0470187 (UMLS CUI [1,3])
C0332268 (UMLS CUI [1,4])
Study Subject Participation Status | Investigational New Drugs
Item
12. participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
13. pregnancy or breastfeeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Childbearing Potential Contraceptive methods Refused | Childbearing Potential Contraceptive methods Unable
Item
14. women of childbearing potential: refusal or inability to use effective means of contraception.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C1705116 (UMLS CUI [1,3])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C1299582 (UMLS CUI [2,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial